Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Matthew Scholz
AddedMar 31, 2024
UpdatedMay 31, 2026
Matthew Scholz

Matthew Scholz

Board Member, Sigma Genetics

CrunchbaseLinkedIn

Matthew Scholz's Career

Sigma Genetics
Sigma Genetics

Seattle, WA, US

Board Member· Board
Oisin Biotechnologies
Oisin Biotechnologies

Seattle, WA, US

Board Member· Board
OncoSenX
OncoSenX

Seattle, WA, US

CEO· C-Suite · Management
Immusoft
Immusoft

Seattle, WA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Matthew Scholz's Career

Sigma Genetics
Sigma Genetics
Seed$120k62016Seattle, WA, US
Board Member· Board

Leadership at Sigma Genetics

Chris PihlChris PihlFounder
Zachary R.Zachary R.Co-Founder

Similar to Sigma Genetics

ExcepgenExcepgenSan Francisco, CA, USGene Therapies, VaccinesExcepgenSan Francisco, CA, US

ExcepGen: A San Francisco-based biotech firm innovating in drug discovery for next-gen therapeutics.

Seed · $4.2M6
Sixfold BioscienceSixfold BioscienceLondon, Greater London, GBest. 2018Sixfold BioscienceLondon, Greater London, GB · est. 2018

Sixfold Bioscience: Pioneering RNA therapy delivery with patented systems.

Seed · $10.6M33
XGenomesXGenomesCambridge, MA, USDNA Sequencingest. 2017XGenomesCambridge, MA, US · est. 2017

XGenomes: Revolutionizing DNA sequencing with fast, accurate, and affordable technology for health monitoring.

Angel · $350k9
Oisin Biotechnologies
Oisin Biotechnologies
Seed$7.1M182014Seattle, WA, US
Board Member· Board

Leadership at Oisin Biotechnologies

Kevin PerrottKevin PerrottCo-Founder
Garry HudsonGarry HudsonCo-Founder
OncoSenX
OncoSenX
Seed$11.7M142017Seattle, WA, US
CEO· C-Suite · Management

Leadership at OncoSenX

John LewisJohn LewisFounder
Kristin BedardKristin BedardBoard Member
Gary HudsonGary HudsonBoard Member

Similar to OncoSenX

OncoSpherixOncoSpherixAtlanta, GA, USCancer Treatmentsest. 2018OncoSpherixAtlanta, GA, US · est. 2018

OncoSpherix, Inc.: Advancing novel cancer treatments with proprietary therapeutics to enhance survival and quality of life.

Seed · $2.9M3
OncolixOncolixHouston, TX, USCancer Treatmentest. 2007OncolixHouston, TX, US · est. 2007

Oncolix: A clinical-stage biotech firm innovating therapeutic proteins for cancer treatment.

Series A · $8.5M30
OncXerna TherapeuticsOncXerna TherapeuticsWaltham, MA, USBiotechnology, Pharmaceuticalsest. 2018OncXerna TherapeuticsWaltham, MA, US · est. 2018

Oncologie Ltd., a China-based precision medicine provider, manufactures innovative biotech products.

Series C · $126.5M11
Seneca TherapeuticsSeneca TherapeuticsBlue Bell, PA, USCancer Therapiesest. 2018Seneca TherapeuticsBlue Bell, PA, US · est. 2018

Seneca, a biotech company, innovates oncolytic immunotherapies for cancer treatment.

Series A · $7.7M7
Immusoft
Immusoft
Series A$49.3M222009Seattle, WA, US
Board Member· Board

Leadership at Immusoft

Sean AinsworthSean AinsworthBoard Member
Julia MooreJulia MooreBoard Member
Stephen HilbertStephen HilbertBoard Member
Mark AhnMark AhnBoard Member
Tony SunTony SunBoard Member

Similar to Immusoft

ImmunoVecImmunoVecSanta Monica, CA, USGene Therapyest. 2019ImmunoVecSanta Monica, CA, US · est. 2019

Santa Monica-based ImmunoVec develops gene therapy treatments for terminal immune system diseases.

Series A · $4.3M6
ImmunisImmunisIrvine, CA, USStem Cell Therapiesest. 2018ImmunisIrvine, CA, US · est. 2018

Immunis: A private biotech firm innovating stem cell treatments for age and disease-related immunity decline.

Series A · $10M8
InimmuneInimmuneMissoula, MT, USImmunotherapeuticsInimmuneMissoula, MT, US

Inimmue: A cutting-edge biotech firm, pioneering next-gen immunotherapeutics.

Series A · $22.6M15
IM TherapeuticsIM TherapeuticsAurora, CO, USTherapiesest. 2015IM TherapeuticsAurora, CO, US · est. 2015

IM Therapeutics: Pioneering HLA-directed platform for innovative therapies in autoimmune diseases.

Series A · $10M5

Matthew Scholz's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailHae-Jin LeeHae-Jin LeeFounder · Naver

People Similar to Matthew Scholz

Stephen CraneStephen CraneCo-Founder · ImmunantMeir TseitlinMeir TseitlinCo-Founder · ImubitRyan JeonRyan JeonCo-Founder · ImmigoMarc HarrisonMarc HarrisonCo-Founder · Impart SecurityJon ClaggJon ClaggCo-Founder · Immertec